Cat. No. 2420
Alternative Name: [pGlu1]-Apelin-13
Biological ActivityHighly potent pyroglutamyl form of apelin-13. Endogenous ligand for apelin APJ receptor (EC50 = 0.37 nM) that displays potent vascular effects in vivo.
(Modifications: X = Glp)
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Tatemoto et al (1998) Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem.Biophys.Res.Comm. 251 471.
Katugampola et al (2001) [125I]-(Pyr1)Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br.J.Pharmacol. 132 1255. PMID: 11250876.
Kagiyama et al (2005) Central and peripheral cardiovascular actions of apelin in conscious rats. Regul.Pept. 125 55. PMID: 15582714.
Kleinz et al (2005) Emerging roles of apelin in biology and medicine. Pharmacol.Ther. 107 198. PMID: 15907343.
If you know of a relevant citation for this product please let us know.
Keywords: [Pyr1]-Apelin-13, supplier, Potent, peptide, agonists, APJ, Receptors, Apelin, adipokines
Find multiple products by catalog number
New Products in this Area
Potent neuropeptide S receptor (NPSR) antagonistTC OT 39
Nonpeptide oxytocin and V2 receptor partial agonist; also a V1a receptor antagonistTolvaptan
Potent and selective vasopressin V2 receptor antagonist; renoprotective and orally activeML 00253764 hydrochloride
Melanocortin MC4 receptor antagonist; brain penetrantGSK 1562590 hydrochloride
High affinity, selective urotensin II (UT) receptor antagonistMA 2029
Potent and selective, competitive motilin receptor antagonist; orally activeANQ 11125
Selective motilin receptor antagonist
August 30 - September 4, 2014
Booth Number: 22